Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults
Recruiting
- Conditions
- Pediatric Cancer
- Interventions
- Other: Data collection
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT04477681
- Locations
- 🇫🇷
CHU Lyon, Lyon, France
🇫🇷Institut Curie, Paris, France
🇫🇷CHU Strasbourg, Strasbourg, France
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
Not Applicable
- Conditions
- Cancer
- Interventions
- Procedure: Tissue samplingProcedure: Blood sampling
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT04349293
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT04341207
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
Not Applicable
- Conditions
- Overweight or Obese Breast Cancer Patients
- Interventions
- Other: The personalized telephone based intervention
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 220
- Registration Number
- NCT04304924
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 130
- Registration Number
- NCT04276376
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Pediatric Hepatic Tumors
Recruiting
- Conditions
- Liver Tumor
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 600
- Registration Number
- NCT04274868
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Phase 1
Terminated
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 25
- Registration Number
- NCT04270864
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
Phase 1
Completed
- Conditions
- High Grade Glioma
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 41
- Registration Number
- NCT04267146
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Centre Léon Bérard, Lyon, France
IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas
Recruiting
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Procedure: transoral resectionRadiation: IMRT
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT04224389
- Locations
- 🇫🇷
Centre Hospitalier InterCommunal, Créteil, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Hôpital la Croix Rousse, Lyon, France
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Phase 3
Recruiting
- Conditions
- High-Risk NeuroblastomaPatient With Insufficient Response Chemoimmunotherapy
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
© Copyright 2025. All Rights Reserved by MedPath